Literature DB >> 21209393

Gene targeting in human pluripotent cells.

D Hockemeyer1, R Jaenisch.   

Abstract

Mouse embryonic stem cells (mESCs) have the ability to differentiate into any cell type and can generate chimeric mice when transplanted into a host blastocyst. This remarkable potential, together with the development of robust gene targeting strategies in mESCs, were essential for establishing the mouse as the most widely used model organism in biomedical research. Recent advances have allowed the isolation of human embryonic stem cells and the derivation of induced pluripotent stem cells. Genetic tools similar to those proven routine in the mouse system are needed to realize the full potential of human pluripotent cells as disease models and putative therapeutics. Gene targeting in human cells, however, has proven to be more difficult, more time-consuming, and less robust than in mESCs. In this chapter, we discuss the strategies that have been used to allow specific genetic modifications in human pluripotent cells. We focus on the novel application of custom-engineered zinc-finger nucleases for gene targeting, which has promise to become a robust tool for efficient genetic manipulation of human pluripotent cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21209393     DOI: 10.1101/sqb.2010.75.021

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  30 in total

1.  Germline modification of domestic animals.

Authors:  L Tang; R González; I Dobrinski
Journal:  Anim Reprod       Date:  2015 Jan-Mar       Impact factor: 1.807

2.  Advancing physiological maturation in human induced pluripotent stem cell-derived cardiac muscle by gene editing an inducible adult troponin isoform switch.

Authors:  Matthew Wheelwright; Jennifer Mikkila; Fikru B Bedada; Mohammad A Mandegar; Brian R Thompson; Joseph M Metzger
Journal:  Stem Cells       Date:  2020-06-16       Impact factor: 6.277

Review 3.  Navigating the epigenetic landscape of pluripotent stem cells.

Authors:  Mo Li; Guang-Hui Liu; Juan Carlos Izpisua Belmonte
Journal:  Nat Rev Mol Cell Biol       Date:  2012-07-23       Impact factor: 94.444

Review 4.  Induced Pluripotent Stem Cells Meet Genome Editing.

Authors:  Dirk Hockemeyer; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2016-05-05       Impact factor: 24.633

5.  Endogenous Telomerase Reverse Transcriptase N-Terminal Tagging Affects Human Telomerase Function at Telomeres In Vivo.

Authors:  Kunitoshi Chiba; Jacob M Vogan; Robert A Wu; Manraj S Gill; Xiaozhu Zhang; Kathleen Collins; Dirk Hockemeyer
Journal:  Mol Cell Biol       Date:  2017-01-19       Impact factor: 4.272

Review 6.  Stem cells and modeling of autism spectrum disorders.

Authors:  Beatriz C G Freitas; Cleber A Trujillo; Cassiano Carromeu; Marianna Yusupova; Roberto H Herai; Alysson R Muotri
Journal:  Exp Neurol       Date:  2012-10-02       Impact factor: 5.330

Review 7.  Use of human pluripotent stem cells to study and treat retinopathies.

Authors:  Karim Ben M'Barek; Florian Regent; Christelle Monville
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

8.  An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells.

Authors:  Federico González; Zengrong Zhu; Zhong-Dong Shi; Katherine Lelli; Nipun Verma; Qing V Li; Danwei Huangfu
Journal:  Cell Stem Cell       Date:  2014-06-12       Impact factor: 24.633

Review 9.  Targeted gene disruption to cure HIV.

Authors:  Daniel Stone; Hans-Peter Kiem; Keith R Jerome
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

10.  Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells.

Authors:  Shin-Ichi Mae; Akemi Shono; Fumihiko Shiota; Tetsuhiko Yasuno; Masatoshi Kajiwara; Nanaka Gotoda-Nishimura; Sayaka Arai; Aiko Sato-Otubo; Taro Toyoda; Kazutoshi Takahashi; Naoki Nakayama; Chad A Cowan; Takashi Aoi; Seishi Ogawa; Andrew P McMahon; Shinya Yamanaka; Kenji Osafune
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.